Rituximab and ocrelizumab could potentially be of interest for controlling disease activity in women with immunologic disorders intending on pregnancy, but more safety data are essential.
Why this matters
To date, data from less than 200 pregnancies in women with neuroimmunologic conditions following exposure to anti-CD20 therapies have been reported, mainly concerning rituximab. It is currently recommended that women cease anti-CD20 therapy at least 6 to 12 months prior to conceiving. Recurrence or rebound of disease activity has been reported in patients discontinuing other disease-modifying therapies such as natalizumab and fingolimod, but not with anti-CD20 therapies.